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Referat: 
Adipositas im Kindes- und Jugendalter erhöht das Risiko für diverse chronische 
Krankheiten und ist aufgrund des epidemischen Anteils weltweit zu einem der größten 
Gesundheitsprobleme geworden. Zunehmende Evidenz zeigt, dass übergewichtige 
Personen, die unter "metabolisch gesunder Fettleibigkeit (MHO)" leiden, gegen Typ 2-
Diabetes mellitus und kardiovaskulären Erkrankungen geschützt sind – im Gegensatz 
zu denen mit einer "metabolisch ungesunden Fettleibigkeit" (MUO). Jüngste Studien 
deuten darauf hin, dass neue Biomarker erfolgreich verwendet werden könnten, um den 
MHO- vom MUO-Phänotyp zu unterscheiden. Erhöte Serumharnsäurespiegel wurde als 
potentieller Risikofaktor für kardiometabolische Erkrankungen beschrieben, aber bisher 
haben nur wenige Studien deren Beziehung zu MHO und MUO innerhalb der 
pädiatrischen Population untersucht. In der vorliegenden Studie wurden die potenziellen 
klinischen und metabolischen Indikatoren, die zur Unterscheidung zwischen MHO- und 
MUO-Phänotypen bei Kindern und Jugendlichen beitragen können, anhand von Daten 
aus einer Studie in Deutschland ausgewertet, im Rahmen derer Daten von 246 
übergewichtigen und adipösen und 212 normalgewichtigen Kindern und Jugendlichen 
erhoben wurden. Dieselben Daten wurden verwendet, um die Beziehung zwischen 
Serum-Harnsäure-Spiegeln und der metabolischen Gesundheit bei übergewichtigen und 
adipösen Kindern und Jugendlichen zu untersuchen. Eine umfassende 
anthropometrische, klinische und metabolische Charakterisierung des metabolischen 
Profils von MHO- und MUO-Phänotypen ist verfügbar. Diese Studie ergab, dass 70% 
der übergewichtigen und adipösen Teilnehmer einen MHO-Status hatten. Der MHO-
Phänotyp war im Allgemeinen durch eine bessere Insulinsensitivität, niedrigere 
Triglycerid (TG)-Spiegel und einen niedrigeren High Density Lipoprotein Cholesterol- 
(HDL-c) im Vergleich zu ihren MUO-Peers charakterisiert. Es wurde gezeigt, dass 
Serumharnsäure mit Parametern verbunden ist, die zur Definition des metabolischen 
 V  
Gesundheitszustands verwendet werden, wie HDL-SDS, TG-SDS, Nüchternglukose 
und Blutdruck. Zusätzlich schien die Serumharnsäure-Konzentration mit C-Peptid- und 
Cystatin C-Konzentrationen assoziiert zu sein. Das in dieser Arbeit vorgestellte 
Forschungsergebnis legt nahe, dass höhere Harnsäurespiegel als zusätzlicher Indikator 
für den MUO-Phänotyp bei übergewichtigen und adipösen Kindern und Jugendlichen 
verwendet werden könnten. 
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"Corpulence is not only a disease itself, but the harbinger of others." 
Hippocrates
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1.1 Obesity and associated diseases, a world health threat   
Obesity is associated with higher incidence of many health problems including 
cardiovascular diseases, type 2 diabetes and several types of cancer [1,2]. These 
complications contribute to a higher likelihood of morbidity and mortality in adulthood [3]. 
At the same time, the current obesity epidemic, which has spread from western to 
developing countries, is affecting even younger individuals. In fact, over the past decades, 
the proportion of overweight and obese children and adolescents has soared globally, 
rendering youth obesity a major focus of public health efforts [4]. A systematic review 
showed that between 1980 and 2013 the prevalence of overweight and obesity in children 
has increased by 47.1% worldwide [5]. Although recent studies conducted in several 
developed countries suggest a stabilization trend in the prevalence of obesity, especially 
among younger children, its prevalence in adolescents continues to increase [1,6]. In 2006, 
evaluating a sample of more than 17,500 young individuals (2-17 years), the German Health 
Interview and Examination Survey for Children and Adolescents (KiGGS) estimated that 
15% of German children and adolescents were overweight and 6.1% were obese [1,7]. 
Globally, the prevalence of childhood obesity is particularly high in Latin America (Mexico, 
Brazil, Chile, Uruguay and Argentina), North Africa, the Middle East, India, and several 
Pacific Island and Caribbean nations [5,8].  
The primary pathway linking overweight and obesity to the development of diseases is 
dysregulated metabolism, which is related to long-term inefficiencies in balancing intake and 
use of energy in the body [9]. As the prevalence of childhood and adolescence obesity 
increases, its health implications are becoming more evident. Obesity developed during 
childhood and adolescence instigates changes in metabolism, vessels and organs, thereby 
increasing the risk of severe cardiometabolic complications and premature death [10]. A 
certain combination of such abnormalities is known as metabolic syndrome (MS) and is 
characterized by high blood pressure, insulin resistance, unfavorable lipid profile (high 
levels triglycerides and/or low levels of cholesterol bound to high-density lipoprotein), liver 
enzymes alterations, abnormalities in fibrinolysis, subclinical inflammation and 
hyperuricemia. The metabolic syndrome has been used to link obesity and cardiovascular 
disease (CVD) risk factors [11,12]. Some studies have reported clustering of CVD risk 
factors among obese children and adolescents and a positive relationship between the level 
of overweight and the prevalence of the metabolic syndrome. A relationship between 
metabolic syndrome during childhood and the risk of CVD has also been observed later life. 
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In addition, excess body fat has been associated with increased risk of musculoskeletal 
conditions and obstructive sleep apnea, chronic pain, asthma and gallbladder [17].  
These effects can reduce quality of life of affected individuals while also placing a 
substantial economic burden on health and social care systems [18]. In 2007, according to 
the World Health Organization, overweight and obesity were linked to about 80% of type 2 
diabetes cases, 35% of ischemic heart disease cases and 55% of hypertension cases among 
adults in Europe. These complications result in more than 12 million life-years of health 
problems and 1 million deaths per year. In Germany, cardiovascular diseases were estimated 
to cause 39% of all deaths [19]. The treatment costs for cardiovascular diseases were 37.4 
billion € in 2014 (equivalent to 1.4% of the gross domestic product GDP) and are projected 
to amount to 41.4 billion in 2020 [20]. 
Despite the substantial progress in research during the last decades, obesity is still difficult to 
manage. In fact, the extent of fat accumulation, its distribution within the body and the 
associated consequences vary considerably between individuals [21]. It is estimated that up 
to 30% of obese individuals do not have obesity-related comorbidities and do not show any 
evidence of metabolic abnormalities. Consequently, they have a reduced risk of developing 
type 2 diabetes mellitus and cardiovascular disease [22]. This subgroup is identified as 
metabolically healthy obese (MHO). However, it is unclear how healthy the individuals of 
this group are and whether MHO could later develop into metabolically unhealthy obesity 
(MUO) [23]. An improved understanding of the underlying mechanisms and the health 
consequences of different obese phenotypes in youth could represent the first step towards 
the prevention of an array of deleterious chronic diseases that commonly emerge throughout 
the life-course and may lead to a beneficial healthy aging process. Considering the 
variability of individuals within the obese population, it would be useful to allocate them 
into more specific groups according to their degree of metabolic abnormalities, aiming at 
early diagnoses and successful treatments, in order to be able to address their needs more 
specifically [24]. 
 
1.1.1 Definitions and classifications of overweight and obesity 
Overweight and obesity are defined as an abnormal or excessive accumulation of body fat 
that poses a health risk [25]. The most commonly used, widely accepted, inexpensive and 
non-invasive indicator for the level of adiposity is the body mass index (BMI, expressed as 
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weight/height2 in kg/m2). BMI has been criticized for not being sensitive enough to detect 
differences in body composition (i.e. fat mass and fat-free mass) [26]. Nevertheless, it is a 
simple and practical method to use. Adults (≥ 18 years) with a BMI ≥ 25 kg/m² are classified 
as overweight and those with a BMI ≥ 30 kg/m² are classified as obese [27]. Regarding 
children and adolescents, however, growth and development at different ages have to be 
taken into account and, therefore, BMI cut-offs used for adults cannot be used. Although 
BMI and fat mass of adults and youths are closely correlated [26], assessing adiposity for 
young individuals is more complicated, as the fat mass changes with age, gender, maturation 
and ethnicity [28]. In addition, to be able to compare weight status between groups of 
children, the definition of childhood overweight and obesity is based on age and sex-specific 
BMI cut-off values – presented in tables or pointed out as centiles on a chart – which are 
generally derived from representative reference population. 
1.2 A ‘metabolic healthy’ type of obesity 
The heterogeneity of the healthy obese phenotype was first described in the 1980s by Sims 
[29] and has repeatedly been confirmed since then [30,31]. Analyses of epidemiological data 
concluded that overweight and obesity are not always associated with the onset of 
cardiovascular disease and increased mortality [32]. Research has focused on disentangling 
the underlying mechanisms that protect obese individuals from metabolic diseases [33]. In a 
follow-up study covering 10 years, Mongraw-Chaffin et al. [34] observed that 24% of obese 
individuals were metabolically healthy and did not develop metabolic syndrome. This means 
that 1 out of 4 individuals who have been obese over long period will not develop metabolic 
complications.  
The main metabolic characteristics of MHO individuals have been reported to be a set of 
favorable metabolic profiles, such as: preserved insulin sensitivity, absence of metabolic 
syndrome criteria, low serum uric acid levels, low inflammatory indicators, favorable lipid, 
immunological and hormonal profiles, and low visceral, hepatic, and muscle fat 
accumulation. However, up to now, little is known about the factors that either delay the 
onset of metabolic disturbances or protect obese individuals from them [35]. Consequently, 
numerous systems have been developed to classify the clustering and the severity of 
metabolic risks associated with obesity. 
Currently, overweight or obese individuals can be classified as metabolically healthy obese, 
according to three definitions: (i) the determination of metabolic risk factor clustering (e.g. 
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favorable lipid profile, normal glycemic status, and the normal blood pressure), (ii) a 
preserved insulin sensitivity, and (iii) the combination of the previous two definitions. 
Nevertheless, there is evidence that the above-mentioned definitions should be broadened by 
considering additional components, such as serum uric acid, inflammation markers and liver 
fat content [36,37]. Insulin sensitivity is predominantly assessed by using the surrogate 
homeostasis model assessment of insulin resistance (HOMA-Index) with subjective cut-offs.  
For instance, Prince et al. [38] defined MHO as the absence of insulin resistance (IR), a well-
established predictor of type 2 diabetes, or as the absence of four traditional cardiovascular 
risk factors: high triglycerides, low HDL cholesterol, high fasting glucose and high blood 
pressure percentile for age, sex and height. Camhi et al. [39] define MHO as  showing at 
least one of the following metabolic risk factors: high blood pressure, high triglycerides, 
high fasting glucose, low HDL cholesterol. A study that evaluated data from German obese 
children, defined MHO as the absence of hypertension, dyslipidemia and impaired fasting 
glucose [40]. Finally, two studies used metabolic syndrome criteria proposed earlier by 
Alberti et al. and defined MHO as waist circumference ≤ 90th percentile together with no 
laboratory criterium of metabolic syndrome definition fulfilled [37,41]. MHO in children 
and adolescents is often defined using the pediatric International Diabetes Federation (IDF) 
criteria [39], the modified NCEP III criteria [42] and the age specific criteria [43] for the 
definition of metabolic syndrome. However, there is still no consensus regarding the number 
of metabolic syndrome criteria that must not be fulfilled to consider obese children and 
adolescent as metabolically healthy. A general overview of criteria sets that have been used 
to define MHO in children and adolescents is presented in Box 1. 
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Box 1. Variables and values used for the definitions of MHO in pediatric population. 
 
Variables Prince RL 
et al 2014 
[38] 
Camhi SM 
et al 2013 [39] 
Reinehr T et al 
2015 [40] 
Mangge H 
et al 2013 [37] 
Weghuber D 
et al, 2013 [41] 
WC    ≥ 90th percentile ≥ 90th percentile 
BP 
 
≥ 90th 
percentile for 
age, sex, and 
height 
≥ 90th 
percentile for 
age, gender, 
and height  
≥ 130/ 85 
mmHg  
≥ 130/85 mmHg 
 
≥ 130/85 mmHg 
 
FPG ≥ 5.6 
mmol/L. 
 
≥ 100 mg/dL  ≥ 100 mg/dl 
 
≥ 5.6 mmol/L. ≥ 5.6 mmol/L. 
TG 
 
≥ 1.25 
mmol/L 
≥ 110 mg/dL 150 mg/dl ≥ 1.7 mmol/L ≥ 1.7 mmol/L 
HDL-cM 
 
≤1.02 
mmol/L 
< 40 mg/dL < 40mg/dl < 1.03 mmol/L  < 1.03 mmol/L  
HOMA-IR ≥ 3.16     
Criteria for 
MHO  
None of the 
above 
≤ 1 of the 
above 
 
None of the 
above 
None of the 
above 
None of the 
above 
MUO criteria ≥ 1of the 
above 
≥2 of the above ≥1 of the 
above 
≥ 3 of the 
above 
≥3 of the 
above 
BMI (percentile) 
 > 85th  
 
> 95th  
 
> 97th   Overweight >85th; 
Obese > 95th  
 
Overweight 
>85th; 
Obese > 95th  
 
WC: waist circumference; BP: blood pressure; FPG: fasting plasma glucose; TG: triglyceride; HDL: high density lipoprotein; 
HOMA-IR: homeostasis model assessment of insulin resistance; MHO: metabolically healthy obesity; MUO: metabolically 
unhealthy obesity; BMI: body mass index. 
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Although MHO in the adult population has been extensively studied, research focusing on 
children and adolescents is scarce. Based on diverse criteria, a recent review reported an 
MHO prevalence in obese children ranging from 18 to 44% [44]. The broad range was 
attributed to geographic distribution, age, sample size differences, different study design and 
different definitions used for obesity and metabolic health. Rey-Lopez et al. showed an even 
higher variability of MHO prevalence from 6% to 75% reported in various publications [45]. 
A recent study conducted in Chinese children and adolescents aged 6- to 18-years-old found 
prevalence of MHO was 3.9%-36.7%, using two different MHO criteria defined by insulin 
resistance and metabolic syndrome components respectively [22]. Data from a recently 
published longitudinal German study, based on a population of obese children, suggested 
that a substantial proportion of young obese (49.3%) displays an MHO phenotype [40]. The 
high variability of MHO prevalence in the aforementioned studies is due to the fact that the 
definition of MHO is still controversial and that no clear criteria have been widely accepted. 
Accumulating evidence indicates that different factors, including lifestyle, sex, age, ethnicity 
and specific cut-off values can largely influence the MHO prevalence [46]. Therefore, 
without a wide consensus on the definition of MHO individuals, the comparability between 
different studies and the successful interpretation of the association between MHO and long-
term health effects remain difficult to achieve. 
 
1.2.1 Distinguishing characteristics of healthy obesity 
 
Although the underlying mechanisms leading to the transition between healthy and 
unhealthy obese phenotypes are poorly understood, several plausible mechanisms have been 
suggested in both human and animal studies [24,35,47]. Therefore, it is of great interest to 
identify additional biomarkers that distinguish between healthy and unhealthy overweight or 
obese individuals. This indicators might be useful to understand the mechanisms and the 
predisposing factors linking metabolic disorders to obesity [48] and could become relevant 
tools for identifying future diseases and to make accurate prognoses. Over the last years, 
several biomarkers have been proposed to distinguish different phenotypes of obesity. A 
biomarker of growing importance is serum uric acid: high levels of uric acid have been 
reported to be a clinically essential cue for inflammations, which are linked to metabolic 
disorders in seemingly healthy individuals [49]. Weghuber et al. [41] examined 299 
overweight/obese children and adolescents and showed that serum uric acid levels were a 
significant predictor of metabolically unhealthy obesity (MUO) in youth populations. Other 
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inflammation markers, such as high-sensitivity C reactive protein (hs-CRP), may also be an 
important component in the cluster of metabolic risk factors [50]. Phillips and Perry [51] 
demonstrated that MHO individuals presented a more favorable inflammatory status than 
their metabolically unhealthy counterparts, including lower concentrations of hs-CRP, 
interleukin 6 and white blood cell count. It has been increasingly suggested to include liver 
fat content in the definition of MHO, because the prevalence of non-alcoholic fatty liver 
disease seems to be significantly lower in MHO individuals [52]. Recently, C-peptide was 
discovered to be a part of the immune response by regulating inflammatory cytokines and 
was associated with MS components [53,54]. This finding suggests that C-peptide 
concentrations might also be a clinically relevant indication of cardiovascular risk associated 
with metabolic disorders [54]. The exact attributes of additional biomarkers characterizing 
different obesity phenotypes have yet to be defined. There is growing scientific and medical 
interest in the MHO subgroup as ramifications of the health-preserving characteristics could 
individualize our current knowledge of chronic disease development [35].  
 
1.3 Physiology of uric acid (UA) 
 
Uric acid was first found in human urinary calculi by Scheele and Bergmann in 1776 
[55,56]. They named the substance lithic acid and proved that it is a common urine 
component. In 1798 George Pearson, after isolating and characterizing uric acid from 200 
urinary calculi specimens, suggested the name uric oxide [57]. The structure of uric acid was 
first proposed by Ludwig Medicus in 1875 [55,58]. Finally, after the pioneering works by 
Medicus, Liebig, and von Baeyer, the complete synthesis of uric acid was successfully 
performed for the first time in 1895 by the future Nobel laureate Emil Fischer [59,60].  
Uric acid is a breakdown product of ingested and endogenously synthesized purines. DNA 
and RNA are degraded into purine nucleotides and bases, which are then metabolized to 
xanthine and uric acid via the action of xanthine oxidase [61]. Uric acid does not undergo 
any further metabolism in humans and is excreted by the kidneys and into the intestinal tract. 
Elevated UA levels can be determined by several causes: increased production, decreased 
excretion, or genetic mutations associated with renal UA transportation [62,63]. Increased 
UA production is associated with purine-rich diets, characterized by high consumption of 
meat, bean seeds, mushrooms or some types of seafood [64]. Moreover, abnormal kidney 
function or competition for excretion with certain medications (e.g. diuretics) can alter the 
excretion of UA, thereby leading to increased UA level [65]. Further causes include high-
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fructose diets and excessive alcohol consumption. Namely, ethanol accelerates adenine 
nucleotide degradation by raising the plasma concentration of xanthine, which breaks down 
to produce UA. In addition, ethanol promotes dehydration by decreasing UA excretion [63].  
Elevated UA levels in the blood can lead to hyperuricemia. This condition develops as a 
result of UA overproduction and/or altered UA secretion and is characterized by unusually 
high UA levels, higher that urate solubility [66]. The increase in consumption of fructose-
containing drinks, food, and table sugar during the last decades has contributed to 
hyperuricemia by increasing the conversion of ATP to inosine, a precursor in purine 
metabolism [67].  
A noteworthy characteristic of serum UA is showing both, pro-oxidative and antioxidative 
effects. In case of acute rises, serum UA acts as an antioxidant at the intravascular level. 
Thanks to this property, serum UA plays the essential role of the major extracellular 
antioxidant of human blood [68], which can benefit the endothelial function. When serum 
UA levels are consistently high, serum UA acts as pro-oxidant at the intracellular level. As a 
result, lipid oxidation increases and the synthesis of nitric oxide, which has anti-
inflammatory and vasodilatory functions, decreases, potentially leading to cardiometabolic 
comorbidities [67,69]. The pivotal role of serum UA in the development of cardiometabolic 
abnormalities was also reported in other studies. For example, it was suggested that 
hyperuricemia may increase the risk of gouty arthritis and nephrolithiasis [70]. Therefore, it 
is of critical importance to understand the processes involved in augmenting serum UA 
levels, which might, in turn, play an active role in contributing to the 
development/progression of metabolic diseases.  
 
1.3.1 Serum UA and cardiometabolic risk factors  
 
The role of serum UA in the development of metabolic disorders has been investigated for 
many decades. Since the link among hyperuricemia, hyperglycemia and hypertension was 
first suggested by Kylin in 1923 [71], there has been a growing interest in the relationship 
between high serum UA levels and other metabolic abnormalities such as hyperglycemia, 
abdominal obesity, dyslipidemia, and hypertension [72,73]. A recent meta-analysis has 
demonstrated that high serum UA levels are associated with a modest increase in episodes of 
infarction and mortality [74]. Recent studies showed that serum UA is linked to 
cardiovascular dysfunction in pediatric obesity [75]. Furthermore, a recent investigation 
involving young individuals with hyperuricemia has suggested that a reduction in serum UA 
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can lead to an increase of body weight and related CVD risk factors  [76]. However, it is still 
not entirely clear whether the cardiovascular effects associated with high UA levels can be 
attributed only to UA - as an independent factor - or whether they are codetermined by the 
presence of other factors [67]. Many studies described correlations between elevated serum 
UA levels, MS and several of its components [62,77,78]. Two distinct mechanisms can 
explain the link between hyperuricemia and Two distinct mechanisms can explain the link 
between hyperuricemia and MS: the first mechanism is related to hyperuricemia - induced 
endothelial dysfunction leading to reduced insulin-stimulated nitric oxidative - induced 
vasodilation in skeletal muscle, and therefore to reduced glucose intake in skeletal muscle 
[79]. A bidirectional causal effect between hyperuricemia and hyperinsulinemia was 
suggested. The second mechanism is related to the fact that uric acid induces oxidative and 
inflammatory alterations in adipocytes, since xanthine oxidoreductase, responsible for 
generating UA from xanthine, which is expressed in adipocytes and is critical to the 
adipogenesis process [80]. Even if the connection between hyperuricemia and MS has not 
been totally understood yet, many studies have described correlations between serum UA 
levels, MS, and several of MS components in children and adolescents [81,82]. Indeed, 
Cardoso et al. [83] suggested an association between high levels of uric acid and MS in 
adolescents. For instance, every 1 kg/m2 increment in BMI is associated with a 5.74 μmol/L 
increase of serum UA levels. These results were further supported by Jones et al. [84]. The 
Bogalusa Heart Study demonstrated that elevated serum UA levels play a pivotal role in the 
pathogenesis of MS already during adolescence, suggesting that serum UA may help the 
early identification of high risk individuals for MS [85]. 
 
1.3.2 Serum UA and type 2 diabetes 
 
Elevated serum UA levels seem to be involved in the development of diabetes: high serum 
UA levels were found to be closely associated with insulin resistance and diabetes mellitus 
type 2 [86]. In particular, one-quarter of diabetes cases can be attributed to high serum UA 
levels. This outcome most likely reflects the biochemical interaction between plasma 
glucose and purine metabolism, which leads to increased excretions of serum UA during 
hyperglycemia and glycosuria [87]. In Germany, a population-based prospective study 
showed that serum UA was a strong risk factor for diabetes [88]. A recent study suggested 
that the increase in serum UA has a positive correlation with insulin resistance in obese 
children and adolescents. It was found that for every increase of 1 mg/dL in serum uric acid 
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levels, there would be a 91% increase in the chance of insulin resistance [89]. It is worth 
mentioning that in prepubertal obese children, elevated levels of serum UA seem to be an 
early metabolic alteration associated with insulin resistance features [90]. Subsequent studies 
revealed that insulin resistance was very low in healthy obese individuals compared to 
unhealthy ones and that it increased significantly with the number of metabolic obesity 
comorbid disorders [41]. Low prevalence of insulin resistance was reported among obese 
individuals without significant comorbidities, suggesting that a preserved insulin sensitivity 
may be the key mechanism underlying healthy obesity [91].  
 
1.3.3 Serum UA and hypertension 
 
Numerous studies have demonstrated that hyperuricemia carries an increased risk for 
development of hypertension independently of other risk factors [62,80]. The strength of the 
relationship between serum UA level and hypertension decreases with increasing individual 
age and duration of hypertension, suggesting that serum UA levels may be more important in 
younger individuals with early-onset hypertension [84]. Several authors have emphasized 
that serum uric acid plays a role in pediatric hypertension. High serum UA levels were 
observed in about 90% of adolescents with recent onset hypertension and the serum UA 
level correlated with BP values [67]. Viazzi et al. [92] found that serum UA was directly 
related to hypertension independently of gender, puberty, BMI, HOMA-IR and renal 
function in children and adolescents. Various studies demonstrated that hypertension could 
lead to hyperuricemia. Hypertension can cause microvascular injury [90,93,94] which then 
leads to a state of tissue hypoxia and to a consequent increase in lactate production, which in 
turn impair the renal clearance of urate. Furthermore, tissue hypoxia also induces the 
production of some precursors of uric acid, such as adenosine, hypoxanthine and xanthine 
oxidase [95]. In addition, recent studies report that hyperuricemia is involved in the 
reduction of nitric oxide release and in the activation of the renin-angiotensin system. Both 
mechanisms cause renal vasoconstriction and, therefore, lead to increased blood pressure 
[96]. Serum UA’s role in hypertension and cardiometabolic risk is demonstrated by the 
increased production of hs-CRP in endothelial and smooth muscle cells when uric acid is 
present [97]. 
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1.3.4 Serum UA and kidney-related complications 
 
Moreover, increasing evidence suggests that high serum UA levels in obese individuals may 
cause kidney damage [98]. A recent study described that chronic kidney disease is related to 
serum UA levels, MS and obesity [99]. One possibility is that underlying mechanisms, such 
as endothelial dysfunction and oxidative stress, might c both kidney damage and the MS 
[100]. Some authors show that diets with high sugar addition, which implicates excess 
fructose, might have a key role in development of MS and kidney disease by elevating serum 
UA [101]. Krishnan et al. showed that the serum UA levels are linked to diabetic retinopathy 
in patients with type 2 diabetes mellitus [102]. Other studies reported that uric acid is 
involved in the reduction of nitric oxide in renal macula densa and in the direct stimulation 
of the renin-angiotensin system, leading to vasoconstriction and higher blood pressure 
[103,104]. In addition, cystatin C, albumin and UA were found to improve the identification 
of risk associated with chronic kidney diseases [105,106].  
 
1.3.5 Connection between Serum UA levels and metabolic health status  
 
Despite the evidence that serum UA is a cardiometabolic risk factor [107], it is rarely 
associated in the literature with the metabolic health status in the young population. Very 
few studies have addressed this association directly. One example is a recent study from 
Mangge et al. that examined the influence of serum uric acid in the development of 
metabolic abnormalities in overweight/obese young individuals. The authors performed a 
cross-sectional investigation analyzing a group of 299 overweight and obese children aged 
8-18 from the STYJOBS/EDECTA cohort, allocated into three subgroups based on their 
weight and the presence of metabolic abnormalities: the normal weight control group, the 
MHO group and the MUO group. The results indicated elevated serum UA as the best 
predictor of unhealthy obesity in young population [37,41]. The emergence of serum UA as 
possible indicator to distinguish between metabolic healthy and unhealthy phenotype is 
believed to have relevant implications for obesity treatment and research in the pediatric 
population. More research would be necessary to consolidate the position of serum UA as a 
clinically relevant indicator of the obesity phenotype in youth, and, perhaps, even a risk 
modifying therapeutic target. 
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THE PROJECT RESEARCH 
 
1.4 Research question and hypotheses  
 
As already stated in previous paragraphs, obesity is one of the most serious health issues 
faced by the current generation of children and adolescents and it should be prevented as 
early in life as possible. It is widely accepted that obese children are at high risk for 
developing metabolic complications that eventually may progress to type 2 diabetes and 
cardiovascular diseases [1]. Timely and carefully planned preventive measures are needed to 
reduce the risk of health-related consequences later in life. However, the concept of 
metabolically “healthy” obesity (MHO) was recently introduced into the field of pediatric 
obesity to describe obese children without any metabolic complications, in contrast to those 
with metabolically unhealthy obesity (MUO) [50]. Because of this, research has been 
focusing on potential clinical and metabolic indicators that may distinguish the MHO from 
MUO phenotypes and that can contribute to a better understanding of associated 
mechanisms. In this thesis, I focused on the distinction between MHO and MUO phenotypes 
and their relationship with serum uric acid in the pediatric population. Currently, there is a 
paucity of studies regarding these topics. Additionally, in this work I examine the possibility 
of using serum uric acid as an indicator of MUO phenotype in obese children and 
adolescents. Serum uric acid has been associated with risks of developing metabolic 
complications such as metabolic syndrome and type 2 diabetes mellitus in seemingly healthy 
obese individuals [108] and, therefore, is a promising health status biomarker for young 
individuals. More specifically, the following research questions are addressed: 
 
1) What are the potential clinical and metabolic indicators that can be used to distinguish 
between MHO and MUO in children and adolescents? 
2)  Is the uric acid a potential indicator for the MUO phenotype in overweight or obese children 
and adolescents? 
3)  Is there a consistent association between serum uric acid and other cardiovascular risk 
factors among children and adolescents in Germany? 
 
 
 
 
 
 
 
1 INTRODUCTION 
 
19 
 
1.5 The LIFE-Child study 
 
The data used in the present study were obtained from the LIFE-Child study, which assessed 
individuals aged 0 to 18 years and is a part of the “Leipzig Research Center for Civilization 
Diseases (LIFE)”, a major research project of the University of Leipzig.   
The LIFE-Child study was designed in 2011 with the broad aim of understanding how and 
through which mechanisms metabolic and environmental factors influence  growth, health 
and development processes in newborns, children and adolescents in Germany [109]. Since 
its inception, LIFE-Child studies have been a source of evidence for the health inequalities in 
children and adolescents in Leipzig, with recent contributions focusing on age-related health 
conditions. Through the data provided by the LIFE-Child study it is possible to investigate 
complex associations between life circumstances, behavior and health outcomes. 
Additionally, LIFE-Child provides reference data for health-related indicators. 
The instruments used for data collection were a combination of interviews and 
questionnaires addressing socio-demographic characteristics, personal, family history, 
anthropometric and laboratory measurements. The participants were recruited by the health 
department, by practicing pediatricians, by inviting school classes and by public relations 
(website, social networking, flyers and events).  
Ethical approval for the study was obtained from the ethics committee of the Medical 
Faculty of the University of Leipzig (file reference: Reg. Nr. 264-10-19042010). Parents or 
legal guardians of the participants gave written informed consent for their data to be used for 
bona fide research purposes of data. 
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Abstract 
Background: Metabolically healthy obesity (MHO) refers to those individuals who do not 
show cardiometabolic abnormalities. Our aim was to identify potential clinical and 
metabolic indicators that may help to distinguish between metabolically healthy and 
unhealthy individuals amongst overweight and obese (ov/ob) children and adolescents. 
Methods: The study involved 246 ov/ob and 212 normal weight individuals enrolled in the 
LIFE-Child study, aged between 6 and 18 years. Overweight/obese individuals without 
cardiovascular risk factors (fasting serum lipids, blood pressure and glucose) were classified 
as MHO. Individuals meeting one or more criteria of cardiovascular risk factors were 
classified as metabolically unhealthy obesity (MUO). Results: Among the 246 ov/ob 
individuals, 173 (70%) were MHO and 73 (30%) were MUO. The MHO individuals were 
younger, more likely to be male and had lower BMI-SDS. In the logistic regression models, 
UA SDS (OR 1.61, 95% CI 1.1 – 2.6, p=. 004), waist circumference SDS (OR 2.50, 95% CI 
1.2 – 6.4, P=. 017), and C-peptide (OR 4.05, 95% CI 3.5 – 91, p=. 003) were significant 
indicators of MUO. Conclusion: Our results suggest that nearly one-third of the ov/ob 
children are already identified as MUO. Serum levels of UA can be used as an indicator of 
unhealthy obesity in youth where lower levels of UA indicate a lower risk and higher levels 
suggest a higher risk of MUO. We note that the relevance of identifying potential indicators 
remains the first most important step in future clinical research. 
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Introduction 
Excessive body fat during childhood and adolescence instigates the first changes in the 
metabolism, vessels, and organs, which may lead to severe cardiometabolic complications, 
such as increased risk of cardiovascular dysfunction, hypertension, dyslipidemia and type 2 
diabetes mellitus [1].  In fact, both overweight and obesity in children have increased by 
47.1% since 1980 [2]. Its multifactorial nature complicates both therapy and prevention, 
rendering it a major problem and an important challenge for public health around the world 
[3]. Although the latest studies from several countries worldwide suggest a stabilization 
trend in the prevalence of obesity, especially among younger children, its prevalence in 
adolescents continues to increase [4]. Paradoxically, increasing evidence shows that a 
subgroup of overweight and obese individuals, reported as “metabolically healthy obesity”, 
seems to be less prone to have the typical obesity-associated metabolic disorders, in contrast 
to those with metabolically unhealthy obesity [5]. The MHO has been identified by a set of 
favorable metabolic profiles, including preserved insulin sensitivity, the absence of criteria 
for metabolic syndrome, increased physical activity, low inflammatory indicators, hepatic fat 
content, and hormonal profile [6]. These factors might differentiate between metabolically 
healthy and metabolically unhealthy obese individuals. Although MHO in adult populations 
has been well-studied, research focused on children and adolescents is far more scarce [7]. 
The reported prevalence of MHO in children varies considerably, ranging from 6% to 75%, 
depending on the classification system used to define this condition [8,9]. Due to a lack of 
consensus, the definition of MHO remains controversial [10]. Therefore, it is essential to 
investigate underlying mechanisms of the metabolically healthy and unhealthy phenotype in 
overweight and obese individuals [11]. Studies aimed at identifying new biomarkers that 
may distinguish the different phenotypes of obesity are required since such indicators could 
become relevant tools for identifying future diseases, making an accurate prognosis and 
planning intervention strategies [12].  
Over the last years, it has been suggested that further biomarkers, such as serum uric acid 
(UA), are associated with risks of developing metabolic syndrome, type 2 diabetes mellitus 
and incident cardiovascular events [13]. In fact, uric acid has been reported to be a clinically 
important marker of inflammation linked to metabolic disorders in seemingly healthy obese 
individuals [14]. Currently, there is a paucity of recent data concerning the relation among 
biochemical variables with MHO and MUO in the pediatric population. On the basis of these 
observations, this study has endeavored 1) to identify potential clinical and metabolic 
indicators that may help to distinguish between metabolically healthy and metabolically 
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unhealthy phenotypes; 2) to explore the relationship between serum uric acid levels and 
metabolic health in overweight and obese children and adolescents. In addition, we 
hypothesized that serum uric acid might be an indicator of the development of adverse 
cardio-metabolic outcomes in obese children and adolescents.  
2 PUBLICATION MANUSCRIPT 
  
26 
 
Methods 
Research design and population 
The participants’ data in the present study were collected from the ongoing "Leipzig 
Research Centre for Civilization Diseases (LIFE)" Child study of the University of Leipzig, 
which initiated in 2011. The instruments used for data collection were a combination of 
examinations and questionnaires addressing demographic issues, personal and family 
history, anthropometric, and laboratory measurements. Full details have been reported 
previously [15,16]. In 801 children and adolescents serum uric acid levels were available 
(LIFE Child cohort). After excluding those who were underweight (BMI-SDS < -1.28), had 
missing values on data required for defining metabolic health status, had any chronic 
diseases, such as diabetes mellitus type 1, diagnosis of liver disease, or were taking any 
medication that affects glucose or lipid metabolism, 458 individuals aged 6-18 years 
remained (Figure 1) for analysis (239 male and 219 female). Among these, 45.2% (n = 207) 
were obese (BMI-SDS ≥ 1.88) and 8.5% (n = 39) were overweight (BMI-SDS between 1.28 
and 1.88) and they were evaluated alongside with 46.3% (n = 212) normal weight control 
group (BMI-SDS between -1.28 and 1.28) [17]. Due to the fact that few participants were 
overweight, we combined overweight and obese for the analyses. This study was approved 
by the Ethical Committee of the University of Leipzig under registration No. 264-10-
19042010. Written informed consent was obtained from parents or legal guardians of the 
participants before the children and adolescents were included in the study. 
Anthropometric and clinical measurements  
Anthropometric and laboratory data were collected by trained health investigators using 
standardized procedures. Body mass index (BMI) was calculated by weight in kilograms 
(kg) divided by the square height in meters (m) (kg/m2). Age- and sex-specific BMI standard 
deviation scores (BMI-SDS) were calculated using the German reference data [17] as 
recommended by the German Working for Pediatric Obesity Consensus Guideline [18]. 
Waist circumference (WC), defined as midpoint between lowest rib and the upper anterior 
iliac spine, was measured using an inelastic tape in centimeters (cm). WC-SDS was 
calculated based on German references [19]. Waist-to-height ratio (WtHr) was calculated as 
waist circumference (cm) divided by height (cm). Pubertal development was assessed 
according to the definition of the Tanner stage of breast development in girls and genital 
stage in boys. Pubertal development was divided into three pubertal stages (Tanner stage I 
was classified as prepubertal; Tanner stage II,  III and IV as pubertal; Tanner stage V as post 
pubertal) [20]. Blood pressure (BP) was measured at the right arm after a 10-minute resting 
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period in the supine position. BP was measured three times with a one-minute interval, and 
the average of all measurements was used for analyses [21]. Participants also completed 
questionnaires related to their demographic characteristics, medical history, alcohol 
consumption, and dietary habits. 
 
Biochemical parameters 
Fasting venous blood samples were collected from individuals at LIFE Child study. The 
measurement of laboratory parameters was performed at the Institute of Laboratory 
Medicine, Clinical Chemistry and Molecular Diagnostics (ILM), University Hospital 
Leipzig. Total cholesterol, triglyceride, HDL-cholesterol, AST, ALT (UV tests), GGT, LDL-
cholesterol, UA, alkaline phosphatase (colorimetric tests) as well as high sensitive C-reactive 
protein (latex-enhanced immunoturbidimetric test) were analyzed in serum samples with 
reagent from Roche Diagnostics using Cobas 8000 System according to the manufacturer 
protocol (Roche Diagnostics GmbH, Mannheim, Germany). Serum cystatin C (CysC) was 
analyzed using the turbidimetric immunoassay (PETIA) Tina-quant® Cystatin C (Roche 
Diagnostics). An oral glucose tolerance test was performed in all individuals according to 
the established recommendations [22]. oGTT derived laboratory data (insulin and glucose 
concentrations) were drawn at baseline and after 15, 30, 60, 90, 120 min. Insulin 
measurement was performed using the fully automated immunoassay systems of Liaison 
(Diasorin, Dietzenbach, Germany) and Cobas ECLIA-test on Cobas 8000 e602 (Roche, 
Mannheim, Germany). Both assays were adjusted for the 1.IRP WHO reference standard. 
Intra-assay and inter-assay coefficients were below 5.7% [23]. Insulin sensitivity we 
examined by the homeostasis model assessment index (HOMA-IR) [24], which was 
calculated using the following formula: HOMA-IR=(Insulin [mU/l]×Glucose [mmol/l])/22.5. 
The whole-body insulin sensitivity index (WBISI), was determined using glucose and 
insulin values during an oral glucose-tolerance test (OGTT) applying the Matsuda 
calculation [25]. 
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Defining metabolic healthy status 
For the purpose of defining metabolic status, the overweight/obese children and adolescents 
have been divided into two groups (i.e. metabolically healthy or metabolically unhealthy 
status) according to the following criteria (Supplemental Table 1): Individuals with the 
presence of at least one of the following cardiovascular risk factors have been classified as 
having MUO: dyslipidemia, defined as i) serum triglycerides (TG) > 95th percentile or ii) 
serum HDL cholesterol (HDL-C) < 5th  percentile according to the American Academy of 
Pediatrics [26]; Hypertension, defined as iii) blood pressure > 95th percentile for height, sex, 
and age [27]; Impaired fasting glucose (IFG), defined as iv) fasting serum glucose ≥ 5.6 
mmol/l. On the contrary, MHO status was based on the absence of hypertension, 
dyslipidemia, and IFG following the definition of Prince et al [8]. The parameters used to 
define metabolic healthy status were standardized because of age dependence. In addition we 
used the 95th percentile as the cut-off for the aforementioned cardiovascular risk factors. 
 
Statistical analysis 
Gaussian distribution of all variables was checked using the Shapiro-Wilk test in addition to 
graphical methods. All data are reported as mean ± standard deviation (if normally 
distributed), and median and interquartile range (if non-normally distributed). Categorical 
data are presented as number (n) and percentage (%). Differences among groups were tested 
using chi-squared test (x2) for categorical variables and Mann-Whitney-Wilcoxon test or t-
test for continuous variables, when appropriate, with a 95% confidence interval (95% CI) 
and the risk difference (RD) between the MHO and MUO groups. We used hierarchical 
linear regression analysis to evaluate the strength of the relationship between serum UA 
concentrations and cardiovascular risk factors. All statistical models were adjusted for age 
and sex. For overweight/obese individuals, logistic regression analysis was performed to 
assess the association between clinical and metabolic variables as independent variables and 
metabolic unhealthy status as dependent variable, controlled for age, sex, pubertal stage and 
BMI-SDS. Furthermore, logistic regression analyses were performed including gender, age, 
pubertal stage, waist circumference, UA, C-peptide, hs-CRP, and albumin in order to 
identify significant indicators of MUO. The regression coefficients are presented as odds 
ratios (ORs) with 95% confidence intervals (CI). In addition, all analyses were performed 
both including and excluding the overweight category; since our analyses generated similar 
results, all children with (BMI-SDS ≥1.28) were included in the final analyses. In order to 
remove the age dependence, we standardized some parameters such as fasting serum 
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glucose, HDL-c, triglycerides, as well as UA levels using a LMS-type method (LMSP) 
implemented in the package gamlss [28]. The age- and sex- specific percentiles were found 
preferable, especially in young children. All results with a p value less than 0.05 were 
considered to be statistically significant. Data analysis was performed using the statistical 
software R (version 3.1.2, R core team, Vienna, Austria) [29].  
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Results 
Anthropometric and metabolic characteristics of the study population are displayed in table 
1. The presented data consists of 246 overweight/obese and 212 normal weight children and 
adolescents (mean age 11.1 ± 2.8 years, 52% male). The mean BMI-SDS was -0.04 ± 0.68 in 
normal weight and 2.32 ± 0.52 in overweight/obese children. 41% of them were classified as 
prepubertal, 47% were pubertal and 12% were postpubertal. Based on the cardiovascular risk 
factors, the overweight/obese individuals were classified into two groups; 173 (38.0% of the 
total study sample) “metabolically healthy obesity” (MHO, no criteria of cardiovascular risk 
factors) and 73 (16.0%) “metabolically unhealthy obesity” (MUO, presence of one or more 
criteria of cardiometabolic risk factors). These two groups were compared to the control 
group (normal weight individuals, 212 [46.0%]). Among the cardiovascular risk factors in 
the MUO individuals, hypertriglyceridemia was the most frequent (in 54.2% of the 
individuals), followed by low serum HDL-C (45.8%), hypertension (19.5%) and IFG 
(14.7%). The MHO individuals were more often prepubertal than MUO individuals. As 
expected MUO group had significantly higher median BMI-SDS when compared to the 
MHO group (table 1). Circulating concentrations of uric acid SDS, C-peptide and hs-CRP 
were significantly higher in MUO compared to MHO group. Additionally, cystatin C levels 
were significantly higher in the controls compared to the MHO and MUO, whereas no 
significant difference was found between MHO and MUO groups. Markers of liver function, 
including ALT, AST and alkaline phosphatase, were similarly increased in MHO and MAO 
groups, exhibiting no differences between them, with the exception of GGT levels, which 
were significantly higher in MUO as compared to the MHO group. The used parameters 
defining the metabolic health status are summarized in table 2. MUO showed significantly 
higher triglycerides SDS, glucose SDS, systolic and diastolic blood pressure SDS compared 
to MHO individuals. As expected, glucose metabolism was altered in MUO as indicated by 
increased insulin levels and reduced WBISI with normal glycaemia compared to the MHO 
group. Anthropometric and biochemical characteristics of all participants of the study are 
presented in Supplemental Table 2. MUO children showed significantly increased LDL 
cholesterol paired with reduced HDL cholesterol SDS when compared to MHO children. 
Hematological indicators, including hemoglobin, red blood cell, platelet, white blood cell 
was increased in the MUO compared to the MHO group, although no significant differences 
were found between both groups. Levels of testosterone and SHBG were higher in the MHO 
in comparison to the MUO group; whereas levels of estradiol were significantly lower in the 
MHO than in the MUO group. However, after stratifying the analyses by Tanner stage to 
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avoid a bias caused by the different age distributions of MHO and MUO, the difference 
pertains only significant for Tanner 1 stage where the MHO group shows significantly lower 
values of estradiol. The results of the hierarchical regression analyses were incorporated to 
examine further the relationship between serum UA and the parameters used to define the 
metabolic health status. They are summarized in Table 3. Uric acid serum concentrations 
were associated with serum triglyceride SDS, systolic blood pressure, CysC and C-peptide. 
Furthermore, UA SDS was negatively associated with serum HDL SDS. However, we did 
not find a significant effect of glucose-SDS on UA serum levels. Additionally, a logistic 
regression analysis was performed to identify indicators of MUO phenotype as shown in 
table 4. Based on the relevant clinical and metabolic variables shown in table 1, the set of 
independent variables like waist circumference, UA, C-peptide, albumin and hs-CRP were 
included in the logistic regression models. Variables used for defining the MUO were not 
included in the logistic regression analysis. In conclusion, higher levels of C-peptide, waist 
circumference SDS, UA SDS and pubertal stage were identified as significant indicators of 
the MUO phenotype. However, no significant effect of sex was found. Higher levels of hs-
CRP and albumin were non-significant MUO indicators when controlled for age, gender, 
pubertal stage and BMI-SDS (table 4). 
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Discussion 
This study was designed to identify potential clinical and metabolic indicators that may 
distinguish between metabolically healthy and metabolically unhealthy phenotypes in 
overweight and obese children and adolescents. The results associating serum uric acid 
levels with the MUO status in youth are of particular interest, considering that such data 
were scarcely available up to now. Our study yielded several important findings:  
(i) Regarding cardiometabolic characteristics, the MHO children were identified to be 
younger and less overweight in terms of BMI-SDS and to have lower waist circumference, 
lower insulin resistance index (HOMA), better insulin sensitivity and lower levels of pro-
inflammatory markers. Such results which are supported by other studies [30,31], may place 
that a subset of overweight/obese children was at relatively low cardiometabolic risk despite 
possessing a high amount of body fat [32]. Interestingly, concerning the liver profile, the 
concentrations of ALT and AST were not significantly different between the MHO and 
MUO children. In contrast to our results, it has been reported that ALT and AST serum 
concentrations have been significantly different between MHO and MUO [33]. These 
findings could also be attributed to a healthier constitution, younger age, effects of the 
ethnicity or smaller sample size of studied participants. However, a study from Canada 
found a significant difference in the levels of GGT in MHO compared to the MUO group 
[34], as in the present work.  
(ii) Another point of interest is that there were higher proportions of MHO (38.5%) in ov/ob 
children and adolescents than described by other authors who evaluated obesity in the 
pediatric age [35,36]. For instance, a recent study examining Chinese children and 
adolescents aged 6- to 18-years found that prevalence rates were 3.9% and 36.7% using two 
different MHO criteria defined respectively by insulin resistance and cardiometabolic 
parameters [37]. Using the same MHO criteria as in the present study, a recently published 
German study on the effect of pubertal status revealed that a large proportion of obese 
children (49.3%) exhibited a MHO status [38]. It is likely that the high variability in reported 
MHO prevalences could be explained by the lack of a standard definition of MHO, specific 
cut-off values, small sample sizes, different age ranges, as well as behavioral differences 
between populations [39–41].  
(iii) A comprehensive logistic regression model identified C-peptide, waist circumference 
SDS, UA SDS, and pubertal stage as indicators of the MUO status.  The current study 
demonstrated significantly higher levels of C-peptide and insulin in the MUO group, when 
compared to MHO, indicating an increased β-cell load. This result might indicate early 
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changes in the glucose metabolism of obese children which could be associated with the 
reduction of insulin sensitivity, as implied by the increased HOMA-IR and the reduced 
WBISI. Previously published results have shown C-peptide to be associated with insulin 
resistance, cardiometabolic abnormalities belonging to the metabolic syndrome, 
dyslipidemia, hypertension hyperuricemia and type 2 diabetes mellitus in both obese 
children and adults [42,43]. Cardellini et al [44] demonstrated an important role of C-peptide 
levels in the chemotactic effect on the inflammatory cells and suggested that it promotes the 
onset of atherosclerosis. To best of our knowledge, this is the first study addressing C-
peptide as potential indicator of MUO in ov/ob children and adolescents. In our study, uric 
acid was found to be a significant indicator of MUO status after adjusting for age, sex, 
pubertal status and BMI-SDS. This finding is in agreement with those recently obtained by 
two Austrian authors, who examined overweight/obese children and adolescents and have 
shown that higher serum UA levels were a significant predictor of metabolically unhealthy 
in young populations [36,45]. In youth, serum UA increases progressively from an early age 
with body growth and a plateau around 15 to 17 years [46]. In our study, concentrations in 
overweight/obese children are significantly higher than in their normal weight peers. This 
may be of particular significance for overweight/obese individuals who may exhibit chronic 
long-term hyperuricemia. In fact, increased UA levels may contribute to endothelial 
dysfunction by instigating antiproliferative effects on endothelium and impairing nitric oxide 
production, therefore, it has been associated with the risk of cardiovascular disease [47]. In 
this study we found that UA was strongly associated with blood pressure. A biological 
explanation for this result is supported by animal models, which showed that after the onset 
of hyperuricemia, hypertension occurs. This indicates that the reduction of nitric oxide in the 
renal macula and the direct stimulation of the renin-angiotensin system are probably the 
mechanisms to cause vasoconstriction and, therefore, increase blood pressure [48]. 
According to our findings, the MUO is characterized by higher albumin and CysC levels as 
compared to the MHO children. In addition, CysC, albumin and UA were found to be 
sensitive in the identification of mild reductions in kidney function, and could potentially 
identify young individuals at high risk for the future development of cardiometabolic 
diseases [49,50]. These facts highlight that the association among UA levels and 
cardiometabolic disorders might be a relevant area of research, recognizing the implications 
of the discovery of potential new indicators and therapeutic targets in individuals with a 
metabolically unhealthy phenotype.  
Furthermore, in our study, the pubertal children had a higher odds of being of MUO 
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phenotype. Reinehr et al [38] showed that entering puberty doubles the risk of switching 
from MHO to MUO. The difference between pubertal stage and cardiometabolic alterations 
may be attributable to the physiological changes of body composition and the influence of 
sex hormones during puberty development [51]. 
The major strength of this study is the description of a comprehensive clinical and metabolic 
analysis of MHO and MUO children and adolescents. However, despite our innovative 
findings, our study has the following limitations: First, the cross-sectional design of the 
study could not reveal any causal relationships between the metabolic health status and the 
investigated indicators. Further assessment of the influence of cardiovascular risk factors 
when obese children enter puberty is necessary. Second, it is essential to reproduce this 
study in a longitudinal research among different young populations. Furthermore, our study 
had a limited sample size, and therefore our observations need to be confirmed in a bigger 
cohort. Lastly, there is no standard definition of MHO. In conclusion, our study is one of the 
few to suggest that high uric acid levels increase the likelihood of MUO. Future longitudinal 
studies in larger populations are required to confirm that uric acid is an indicator of 
metabolic phenotypes associated with obesity, and that it may represent a useful indicator to 
identify children with increased cardiometabolic risk. 
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Tables 
 
Table 1. Anthropometric and metabolic characteristics of normal weight controls, MHO and MUO children 
  
   
RD (95% CI) P 
valuea P valueᵇ  
Normal weight 
controls 
MHO   
 
MUO  
 
             
n (%) 212 (46) 173 (38) 73 (16)    
Baseline characteristics, anthropometry 
Age, years 11.1 ± 2.98 11.2 ± 2.64 11.4 ± 2.84 0.20 (0.03-0.98) .610 .785 
Male sex, n (%) 109 (51) 96 (55) 34 (49)  .496 .496 
Pubertal status, (%)     .048 .048 
   Prepubertal 45.9 35.1 34.1    
   Pubertal 44.8 47.3 52.2    
   Postpubertal 9.3 17.6 13.7    
BMI, SDS -0.04 ± 0.68 2.32 ± 0.52 2.57 ± 0.57 0.25 (0.09-0.38) <.001 .001 
Waist circumference, SDS -0.2  ± 0.69 1.62 (1.33-1.89) 1.83 (1.54-2.04)  0.39 (0.05-0.27) <.001     .000 
Metabolic characteristics       
HOMA-IR 1.44 (1.00-1.91) 3.05 (2.50-3.67)  3.66 (2.61-4.70) 0.61 (1.01-2.23) <.001 <.001 
WBISI 5.31 (3.79-7.51) 4.31 (1.98-3.71) 2.00 (1.40-2.47)   0.94 (0.57-1.50) <.001 <.001 
C-peptide, nmol/L 0.58 (0.42-0.69) 0.79 (0.64-0.97) 0.97 (0.73-1.19) 0.18 (0.08-0.25) <.001 <.001 
Uric acid, SDS -0.49 ± 0.85 0.33 (0.01-0.81)  0.69 (0.21-1.39)  0.36 (0.16-0.67) <.001 <.001 
AST, U/L 30.5 (24.7-34.8) 27.4 (22.9-34.4) 30.8 (23.2-35.3) 3.40 (1-20-3.61) .172 .411 
ALT, U/L 17.4 (14.5-21.7) 18.1 (14.5-21.7) 18.7 (15.5-23.4) 0.60 (0.21-0.84) .209 .187 
GGT, U/L 12.1 (10.3-13.9) 12.8 (10.9-15.7) 13.9 (11.5-17.5) 1.10 (0.01- 2.40) .004 .008 
hs-CRP, mg/l 0.36 (0.24-0.67) 0.48 (0.30-1.58) 0.55 (0.27-1.28) 0.07 (0.06-0.13) .007 .048 
Albumin, mg/l 44.5 (43.4-46.8) 45.0 (44.3-47.2) 46.8 (44.7-47.5) 2.30 (0.09-2.90) .004 .030 
Cystatin C, mg/dL 0.84 (0.78-0.90) 0.88 (0.85-1.00) 0.92 (0.87-1.01) 0.04 (0.01-0.04) <.001 0.87 
Data are presented as mean ± SD or median (interquartile range), item risk difference (RD) between the MHO and MUO groups, 
confidence interval (CI). Categorical variables were compared by chi-quadrate test; Group comparisons were analyzed by a Mann-
Whitney-Wilcoxon test or t-test depending on the distribution of data. ᵃP values for Normal weight vs. MHO vs. MUO. bP values for MHO 
vs. MUO. Abbreviations: MHO, metabolically healthy obesity, MUO, metabolically unhealthy obesity, BMI body mass index.
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Table 2. Overview of the parameters used to define the metabolic health status 
 
   
RD (95% CI) Pvaluea P valueᵇ  
Normal weight 
controls MHO   MUO  
            
n (%) 212 (46.0) 173 (38.0) 73 (16.0)    
HDL, SDS 0.11 ± 0.9 -0.63 ± 0.73 -1.51 (1.03-2.01)     0.88  (0.74-1.12) <.001 <.001 
Triglycerides, SDS -0.14 ± 0.88 0.49 (0.17-0.85)  1.78 (0.74-2.14)     1.29  (0.91-1.38) <.001 <.001 
Fasting glucose, mmol/L 4.78 (4.53-5.01) 4.87 (4.70-5.05)  4.95 (4.69-5.17)     0.08 (0.01-0.19)  .009 .047 
Systolic BP, SDS -0.02 ± 0.63  0.18 (0.17-0.64) 0.56 (0.18-1.10) 0.38 (0.07- 0.54) <.001 .003 
Diastolic BP, SDS 0.13 ± 0.47 0.44 (0.16-0.76) 0.63 (0.24-1.01) 0.19 (0.14-0.33) <.001 .002 
Data are presented as mean ± SD or median (interquartile range), item risk difference (RD) between the MHO and MUO groups, 
confidence interval (CI). comparisons were analyzed by a Mann-Whitney-Wilcoxon test or t-test depending on the distribution of data. ᵃP 
values for Normal weight vs. MHO vs. MUO. bP values for MHO vs. MUO. Abbreviations: MHO, metabolically healthy obesity, MUO, 
metabolically unhealthy obesity, HDL-C high density lipoprotein cholesterol, BP blood pressure. 
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Table 3. Results of hierarchical regression analyses between uric acid-SDS and each parameters used to define metabolic health status  
Variables R2 Β P value 
Fasting glucose, mmol/L .538 .135 .081 
Triglycerides, SDS .542 .269 <.001 
HDL, SDS .768 -.247 <.001 
Systolic BP, SDS .574 2.57 <.001 
Diastolic BP, SDS .626 1.87 <.001 
Cystatin, mg/dL .441 .148 <.001 
C-peptide, nmol/L .559 .161 <.001 
Abbreviations: β = regression coefficient, HDL, high-density lipoprotein. All calculations were adjusted for sex and age. 
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Table 4. Results of logistic regression models analysis of clinical and metabolic variables including MUO status as the dependent variable 
 Model1 (Nagelkerke R2 0.060) OR 95% CI Exp(B) P value 
  Age 0.98 0.8-1.2 .777 
  Female gender 1.35 0.7-2.6 .214 
  Pubertal development stage 
     Pre-pubertal 1.90 0.1-4.3 .648 
     Pubertal 1.40 1.1-4.4 .010 
  Waist circumference SDS 2.50 1.2-6.4 .017 
Model 2  (Nagelkerke R2   0.353) OR 95% CI Exp (B) P value 
  Uric acid SDS 1.61 1.1-2.6 .004 
  C-peptide (nmol/l) 4.05  3.5-91  .003 
 Albumin (g/l) 0.98 0.8-1.2 .829 
  hs-CRP (mg/l) 0.93 0.7-1.1 .414 
Abbreviations OR = Odds Ratio per unit increase, CI = Confidence interval, MUO, metabolically unhealthy obesity. Male and post-
pubertal stage as references. Model 1: unadjusted for confounding factors, Model 2: adjusted for age, sex, pubertal stage and BMI-SDS. 
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Übergewichtige Personen, die keine fettleibigkeitsbedingten metabolischen Komplikationen 
zeigen, wurden als "metabolisch gesund fettleibig" (MHO, Metabolically healthy obesity) 
definiert. Im Gegensatz zu metabolisch ungesunden fettleibigen (MUO, Metabolically 
unhealthy obesity) Individuen zeigen MHOs keine metabolischen Störungen wie 
Bluthochdruck, Dyslipidämie, Insulinresistenz und Entzündung [50]. Aufgrund des Mangels 
an allgemein akzeptierten Kriterien ist die genaue Definition des MHO-Status jedoch immer 
noch umstritten. Es wird allgemein angenommen, dass die MHO-Definition von der 
Einführung zusätzlicher Biomarker profitieren könnte, welche wiederum zur Klärung der 
zugrunde liegenden Mechanismen metabolischer Komplikationen herangezogen werden 
können [24]. Darüber hinaus hat sich die klinische Forschung hauptsächlich auf Erwachsene 
konzentriert, und es liegen nur wenige Studien zu MHO bei jungen Menschen vor. Daher 
wird die Untersuchung des MHO-Status in der jungen Bevölkerung unter Verwendung gut 
etablierter und potentiell neuer Indikatoren als wesentlich angesehen, um einen positiven 
Beitrag zur Prävention und/oder Behandlung von zukünftigen fettleibigkeitsbezogenen 
Krankheiten zu leisten. Unter den möglichen neuen Biomarkern wurde festgestellt, dass 
Serumharnsäure (Serum-UA) eine wichtige Rolle als kardiometabolischer Risikofaktor [22] 
für Adipositas-assoziierte Komorbiditäten bei Kindern und Jugendlichen spielt. Dennoch 
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haben nur wenige Studien den Zusammenhang zwischen dieser biochemischen Variablen 
und MHO in der jungen Bevölkerung untersucht. Der Schwerpunkt der vorliegenden Studie 
lag auf der Identifizierung potenzieller klinischer und metabolischer Indikatoren, die zur 
Unterscheidung zwischen MHO- und MUO-Phänotypen beitragen können. Die 
anthropometrischen, klinischen und biochemischen Merkmale von 458 Kindern und 
Jugendlichen wurden analysiert und diskutiert. MHO- und MUO-Individuen repräsentieren 
38% bzw. 16% der dieser Grupe. Der häufigste kardiovaskuläre Risikofaktor bei MUO-
Patienten war Hypertriglyceridämie (54,2%), gefolgt von niedrigem Serum-HDL-C (45,8%), 
Hypertonie (19,5%) und gestörter Glukosetoleranz (14,7%). Zusammenfassend deuten diese 
Ergebnisse darauf hin, dass eine frühzeitige Identifizierung von MUO in der Jugend möglich 
ist, wodurch eine frühzeitige Erkennung möglicher metabolischer Komplikationen 
gewährleistet ist. Verglichen mit der MUO-Gruppe zeigten MHO-Individuen niedrigere 
Nüchterninsulinwerte, Triglyceride, Blutdruck, Nüchternglucose und höhere 
Insulinsensitivität sowie niedrigere Serumharnsäure-, hs-CRP-, Albumin- und C-
Peptidspiegel. Interessanterweise wurden im Gegensatz zu früheren Studien in den MHO- 
und MUO-Gruppen ähnlich hohe Werte für die Marker der Leberfunktion, einschließlich der 
zirkulierenden Konzentrationen von ALT, AST und alkalischer Phosphatase, festgestellt. 
Dieses Ergebnis legt nahe, dass niedrigere Leberenzyme zu dem günstigen metabolischen 
Profil von MHO-Individuen beitragen könnten. Darüber hinaus fördert diese Forschung ein 
besseres Verständnis der Wirkung potenzieller Indikatoren, die verwendet werden können, 
um MHO von MUO zu unterscheiden, insbesondere mit dem Fokus auf Serum-UA. Die 
Ergebnisse dieser Arbeit zeigen, dass Serum-UA mit mehreren kardiometabolischen 
Risikofaktoren assoziiert ist, die normalerweise mit Fettleibigkeit in Verbindung gebracht 
werden, wie Serumtriglycerid SDS, systolischer Blutdruck, C-Peptid und Cystatin C. Keine 
signifikante Beziehung zwischen Glukose-SDS und Serum-UA-Spiegeln wurde gefunden. 
Höhere Serumspiegel von UA erwiesen sich als signifikanter Indikator für den MUO-
Phänotyp. Höhere C-Peptid-Spiegel, Taillenumfangs-SDS und Pubertätstadium sind mit 
einer höheren Wahrscheinlichkeit des MUO-Status assoziiert. Umgekehrt zeigte das 
Geschlecht der Person keine signifikante Wirkung. Hs-CRP und Albumin waren keine 
signifikanten MUO-Indikatoren, wenn sie nach Alter, Geschlecht, Pubertät und BMI-SDS 
kontrolliert wurden. Die in dieser Arbeit präsentierten Ergebnisse könnten für eine bessere 
Unterscheidung zwischen MUO- und MHO-Phänotypen nützlich sein und 
adipositasbedingte Komorbiditäten frühzeitig im Leben behandeln. Längsschnittstudien in 
größeren Kohorten mit jüngeren Individuen werden als ein vernünftiger nächster Schritt 
3 ZUSAMMENFASSUNG DER ARBEIT 
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angesehen, um das Ergebnis dieser Arbeit zu bestätigen und zu erweitern. Mögliche 
zukünftige Untersuchungen könnten zusätzliche Eigenschaften und Wirkungen von 
MHO/MUO-Indikatoren betreffen. Zum Beispiel, wie der Serum-UA-Spiegel durch Konsum 
zuckergesüßter Erfrischungsgetränke und Alkohol beeinfluss wird. 
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Table 1. Metabolic healthy status  
Criteria Cardiovascular risk factors (CRF) MHO MUO 
 Hypertension:  
SBP ≥ 95th percentile or  
DBP ≥ 95th percentile  
 
Dyslipidemia: 
TG ≥ 95th percentile or HDL-C < 5th 
percentile 
  
Impaired fasting glucose ≥ 5.6 mmol/L  
No CRF < 2 of the CRF 
MHO - Metabolically healthy Obesity; MUO - Metabolically unhealthy Obesity; SBP - Systolic blood pressure; DBP - 
diastolic blood pressure; TG - Triglycerides; HDL-C High density cholesterol 
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Table 2. Anthropometric and biochemical characteristics of  normal weight controls, MHO and MUO children 
 
Normal weight 
controls 
 
MHO   
 
MUO  
 
RD (95% CI) 
P 
valuea 
P valueᵇ  
n (%) 212 (46.0) 173 (38.0) 73 (16.0)    
Baseline characteristics, anthropometric 
Age, years 11.1 ± 2.98 11.2 ± 2.64 11.4 ± 2.84 0.20 (0.03-0.98) .610 .785 
Male sex, n (%) 109 (51) 96 (55) 34 (49)  .496 .496 
waist to height ratio, cm 0.42 ± 0.03 0.54 (0.51-0.58) 0.56 (0.53-0.61)  0.02 (0.00-0.04) <.001 .004 
Neck circumference, 
SDS 
-0.12 ± 0.78 1.37 (0.95-1.72) 1.54 (1.04-2.10) 0.17 (0.02-0.41) <.001 .006 
Biochemical parameters 
Total-cholesterol, 
mmol/L 
4.04 (3.68-4.52) 4.11 (3.71-4.65) 4.37 (3.88-4.99) 
   0.26 (0.01-
0.45) 
.043 .039 
LDL-C, mmol/L 2.23 (1.87-2.64) 2.43 (2.05-2.84) 2.73 (2.26-3.17) 
   0.30 (0.08-
0.46) 
<.001 .004 
Fasting insulin, μU/L 7.86 (5.55-10.3) 14.2 (11.0-16.8) 17.3 (13.0-20.3) 
    3.10 (4.42-
9.64) 
<.001 <.001 
HbA1C, % 5.02 ± 0.31 5.08 ± 0.36 5.12 (4.91-5.30) 0.04 (0.02- 0.13) .033 .379 
Haemoglobin, g/dL 13.07 ± 0.94 12.8 ±1.02 13.1 (12.6-13.5) 0.30 (0.00-0.50) .210 .429 
Red blood cell, 10^12 4.70 ±  0.33 4.72 ± 1.56 4.76 (4.54-4.95) 0.04 (0.04-0.13) .131 .078 
Hematocrit, % 0.38 (0.36-0.39) 0.37 (0.36-0.40) 0.38 (0.37-0.40) 0.01 (0.00-0.01) .561 .339 
White blood cell, 10^9L 5.74 ± 1.55 6.45 ± 1.56 6.60 (5.80-7.60) 0.15 (0.79-0.99) <0.001 .133 
Platelet, 10^9L 279.2 ± 58.8 274 (248-315) 286 (264-331) 12.0 (2.99-32.0) .040 .052 
Neutrophils, 10^9L 2.48 (2.01-3.12) 3.22 (2.56-3.96) 3.65 (2.44-4.31) 
     0.43 (0.12-
0.63) 
.002 .173 
Monocyte, 10^9L 0.49 (0.38-0.57) 0.51 (0.42-0.63) 0.50 (0.42-0.62) 0.01  (0.12-0.63) .012 .907 
Alkaline phosphatase, 
U/l 
3.65 ± 1.46 4.01 (3.23-4.62) 4.40 (2.59-5.02) 0.39 (0.23- 0.54) .029 .442 
Total protein (g/l) 68.1 ± 4.30 70.4 ± 3.53 70.7 (68.2-72.6) 0.30 (0.30-1.40) .002 .264 
Creatine kinase, µkat/l 1.99 (1.55-2.71) 1.89 (1.49-2.45) 1.79 (1.55-2.49) 0.18 (0.10- 0.28) .108 .864 
Lpa-Lipoprotein-a, g/l 0.09 (0.04-0.29) 0.10 (0.03-0.31) 0.07 (0.03-0.20) 0.03 (0.00- 0.04) .517 .211 
Interleukin 6, pg ml 1.76 (1.50-3.07) 1.50 (1.50-2.78) 1.86 (1.50-3.01) 0.36 (0.01- 0.50) .723 .325 
Testosterone, nmol/l 0.40 (0.08-2.28) 0.39 (0.08-0.98) 0.37 (0.11-1.32) 0.02 (0.08-0.22) .968 .931 
Estradiol, pmol/l 35.8(18.4-115.5) 18.4 (17.0-94.4) 41.6 (16.4-86.8) 23.2 (0.02-21.1) .050 .042 
Shbg, nmol/l 77.5 (47.3-116) 92.1(60.5-130) 78.2 (42.2-117) 13.9 (27.2-39.0) .123 .158 
Data are presented as mean ± SD or median (interquartile range), item risk difference (RD) between the MHO and MUO groups, confidence interval (CI). 
Group comparisons were analyzed by a Mann-Whitney-Wilcoxon test or t-test depending on the distribution of data. ᵃP values for Normal weight vs. MHO vs. 
MUO. bP values for MHO vs. MUO. Abbreviations: MHO, metabolically healthy obesity, MUO, metabolically unhealthy obesity, LDL-C low high density 
lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gammaglutamyltransferase, HbA1c glycated hemoglobin A1c, 
Lp(a) Lipoprotein-a, hs-CRP high sensitivity C-reactive protein. 
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